Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Fractyl Health, Inc. ( (GUTS) ) is now available.
On June 23, 2025, Fractyl Health, Inc. announced positive 3-month data from the REVEAL-1 cohort of its REMAIN-1 pivotal study, indicating that its Revita procedure may help maintain or further weight loss after GLP-1 therapy discontinuation. The study showed that 12 of 13 participants maintained or lost weight, with no serious adverse effects reported. Additionally, Fractyl presented promising preclinical data on its Rejuva Smart GLP-1 pancreatic gene therapy platform, which prevented obesity and hyperglycemia in animal models. These findings support further development of Fractyl’s metabolic disease therapies, with upcoming data readouts expected to reinforce Revita’s potential in post-GLP-1 weight maintenance.
The most recent analyst rating on (GUTS) stock is a Buy with a $13.00 price target. To see the full list of analyst forecasts on Fractyl Health, Inc. stock, see the GUTS Stock Forecast page.
Spark’s Take on GUTS Stock
According to Spark, TipRanks’ AI Analyst, GUTS is a Neutral.
Fractyl Health’s overall score is driven by significant financial challenges and a negative valuation outlook, despite positive market momentum and strategic advancements in clinical trials and intellectual property. The company’s reliance on external financing and negative equity are major risks.
To see Spark’s full report on GUTS stock, click here.
More about Fractyl Health, Inc.
Fractyl Health, Inc. is a metabolic therapeutics company based in Burlington, MA, focused on innovative treatments for metabolic diseases such as obesity and type 2 diabetes (T2D). The company aims to shift from chronic symptomatic management to durable, disease-modifying therapies targeting the root causes of these diseases. Fractyl Health’s lead product candidate, Revita, is designed to remodel the duodenal lining to address metabolic disease, while its Rejuva platform focuses on developing gene therapies for obesity and T2D.
Average Trading Volume: 302,801
Technical Sentiment Signal: Buy
Current Market Cap: $104.8M
Find detailed analytics on GUTS stock on TipRanks’ Stock Analysis page.